JP2025106475A5 - - Google Patents

Info

Publication number
JP2025106475A5
JP2025106475A5 JP2025064503A JP2025064503A JP2025106475A5 JP 2025106475 A5 JP2025106475 A5 JP 2025106475A5 JP 2025064503 A JP2025064503 A JP 2025064503A JP 2025064503 A JP2025064503 A JP 2025064503A JP 2025106475 A5 JP2025106475 A5 JP 2025106475A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
dose
compound
patient
cardiomyopathy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025064503A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025106475A (ja
Filing date
Publication date
Priority claimed from PCT/US2020/033438 external-priority patent/WO2020236736A1/en
Application filed filed Critical
Publication of JP2025106475A publication Critical patent/JP2025106475A/ja
Publication of JP2025106475A5 publication Critical patent/JP2025106475A5/ja
Pending legal-status Critical Current

Links

JP2025064503A 2019-05-19 2025-04-09 収縮不全の処置 Pending JP2025106475A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201962849936P 2019-05-19 2019-05-19
US62/849,936 2019-05-19
US201962852739P 2019-05-24 2019-05-24
US62/852,739 2019-05-24
PCT/US2020/033438 WO2020236736A1 (en) 2019-05-19 2020-05-18 Treatment of systolic dysfunction and heart failure with reduced ejection fraction with the compound(r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-n-(isoxazol-3-yl)piperidine-1-carboxamide
JP2021568909A JP2022535195A (ja) 2019-05-19 2020-05-18 収縮不全の処置

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021568909A Division JP2022535195A (ja) 2019-05-19 2020-05-18 収縮不全の処置

Publications (2)

Publication Number Publication Date
JP2025106475A JP2025106475A (ja) 2025-07-15
JP2025106475A5 true JP2025106475A5 (https=) 2026-03-11

Family

ID=70978663

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021568909A Withdrawn JP2022535195A (ja) 2019-05-19 2020-05-18 収縮不全の処置
JP2025064503A Pending JP2025106475A (ja) 2019-05-19 2025-04-09 収縮不全の処置

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021568909A Withdrawn JP2022535195A (ja) 2019-05-19 2020-05-18 収縮不全の処置

Country Status (16)

Country Link
US (2) US20220265629A1 (https=)
EP (1) EP3972597A1 (https=)
JP (2) JP2022535195A (https=)
KR (1) KR20220009440A (https=)
CN (1) CN114173782A (https=)
AU (2) AU2020279710A1 (https=)
BR (1) BR112021023074A2 (https=)
CA (1) CA3138080A1 (https=)
CL (1) CL2021003045A1 (https=)
CO (1) CO2021015505A2 (https=)
IL (1) IL288051A (https=)
MX (2) MX2021014109A (https=)
PE (1) PE20220426A1 (https=)
SG (1) SG11202112723PA (https=)
TW (2) TW202541801A (https=)
WO (1) WO2020236736A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114127061A (zh) 2019-07-16 2022-03-01 迈奥卡迪亚公司 (r)-4-(1-((3-(二氟甲基)-1-甲基-1h-吡唑-4-基)磺酰基)-1-氟乙基)-n-(异噁唑-3-基)哌啶-1-甲酰胺的多晶型物形式
CN115487175B (zh) 2019-09-20 2024-05-14 深圳信立泰药业股份有限公司 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物治疗心衰的用途
WO2021257456A1 (en) * 2020-06-15 2021-12-23 MyoKardia, Inc. Treatment of atrial dysfunction
NL2026511B1 (en) * 2020-09-21 2022-05-24 Sulfateq Bv Compounds for treatment of heart failure
WO2023102452A1 (en) * 2021-12-02 2023-06-08 Tenax Therapeutics, Inc. Use of a combination of levosimendan and an sglt-2 inhibitor to treat heart failure
CN116082326B (zh) * 2022-12-16 2024-12-27 药康众拓(江苏)医药科技有限公司北京分公司 一种氘代吡唑磺酰甲基-哌啶异噁唑脲类化合物及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2403533A (en) * 2003-06-30 2005-01-05 Orion Corp Atrial natriuretic peptide and brain natriuretic peptide and assays and uses thereof
US20050250789A1 (en) * 2004-04-20 2005-11-10 Burns David M Hydroxamic acid derivatives as metalloprotease inhibitors
US8324178B2 (en) * 2008-10-31 2012-12-04 The Regents Of The University Of California Method of treatment using alpha-1-adrenergic agonist compounds
JP2014088342A (ja) * 2012-10-30 2014-05-15 Kowa Company Ltd ベンゾオキサジアゾール誘導体を有効成分とするｍｋ２阻害剤
EP4234017B1 (en) * 2015-01-22 2026-04-15 MyoKardia, Inc. Preparation of 4-methylsulfonyl-substituted piperidine urea compounds useful for the treatment of cardiac disorders such as dilated cardiomyopathy (dcm)
WO2019006325A1 (en) * 2017-06-30 2019-01-03 Equalaire Systems, Inc. VENT CAP OF HUB CAP
DK3645002T3 (da) * 2017-06-30 2024-12-16 Amgen Inc Fremgangsmåder til behandling af hjertesvigt med hjerte-sarkomer-aktivatorer

Similar Documents

Publication Publication Date Title
JP2025106475A5 (https=)
JP2022535195A5 (https=)
Cicoira et al. Relation of aldosterone “escape” despite angiotensin-converting enzyme inhibitor administration to impaired exercise capacity in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy
Gartzonikas et al. Current and emerging perspectives on pathophysiology, diagnosis, and management of hypertrophic cardiomyopathy
LINDE‐EDELSTAM et al. Longevity in patients with high degree atrioventricular block paced in the atrial synchronous or the fixed rate ventricular inhibited mode
Blume et al. Prospective single-arm protocol of carvedilol in children with ventricular dysfunction
JP2023529502A5 (https=)
US12343350B2 (en) Istaroxime-containing intravenous formulation for the treatment of acute heart failure (AHF)
US20240091203A1 (en) Methods for treating non-obstructive hypertrophic cardiomyopathy
Greenberg Medical management of patients with heart failure and reduced ejection fraction
Zhang et al. Management of hypertrophic cardiomyopathy
Argirò et al. Safety and efficacy of ranolazine in hypertrophic cardiomyopathy: real-world experience in a National Referral Center
WO2024097284A1 (en) Mavacamten and derivatives thereof for use in treating atrial dysfunction
Rossi et al. Effects of ivabradine on right ventricular systolic function in patients with chronic obstructive pulmonary disease and cor pulmonale
Ramadan et al. Omecamtiv mecarbil in systolic heart failure: clinical efficacy and future directions of a novel myosin-activating inotropic agent
Shono et al. Glucocorticoid-sensitive paroxysmal atrial fibrillation, sick sinus syndrome, and mitral regurgitation in a patient with malignant rheumatoid vasculitis
Abel et al. Prognostic value of mitral valve regurgitation in patients with heart failure with mildly reduced ejection fraction
Chen Heart failure with preserved ejection fraction in older adults
Talerico et al. A case of transient constrictive pericarditis after COVID-19
Steffen et al. Prognostic impact of left ventricular dilatation in heart failure with mildly reduced ejection fraction
Džubur et al. Cardiomyopathies
TH2101007135A (th) เภสัชภัณฑ์สำหรับการรักษาการทำหน้าที่ความผิดปรกติช่วงหัวใจบีบตัวและภาวะหัวใจ ล้มเหลวที่มีสัดส่วนการบีบตัวของหัวใจที่ลดลง
Galas et al. The differences between ambulatory and hospitalized heart failure patients who have mildly reduced or preserved ejection fractions: lessons learned from the HF-POL study
Șuș et al. To pace or not to pace? Or how to pace?
Suzuki et al. Impact of Corticosteroid Use on the Clinical Response and Prognosis in Patients with Cardiac Sarcoidosis who Underwent an Upgrade to Cardiac Resynchronization Therapy